Rac1 signaling protects monocytic AML cells expressing the MLL-AF9 oncogene from caspase-mediated apoptotic death
暂无分享,去创建一个
[1] G. Roboz. Current treatment of acute myeloid leukemia , 2012, Current opinion in oncology.
[2] David A. Williams,et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. , 2012, Blood.
[3] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[4] Wei Li,et al. An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro , 2011, Molecular and Cellular Biochemistry.
[5] David A. Williams,et al. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. , 2011, Blood.
[6] Thomas Helleday,et al. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.
[7] K. Lackner,et al. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity , 2011, Cell Death and Disease.
[8] B. Löwenberg,et al. Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Hess,et al. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. , 2011, Experimental hematology.
[10] Todd D. Westergard,et al. Phosphorylation of MLL by ATR is Required for Execution of Mammalian S Phase Checkpoint , 2010, Nature.
[11] Jiaying Tan,et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. , 2010, Cancer cell.
[12] Tatsushi Yoshida,et al. Blockade of Rac1 Activity Induces G1 Cell Cycle Arrest or Apoptosis in Breast Cancer Cells through Downregulation of Cyclin D1, Survivin, and X-Linked Inhibitor of Apoptosis Protein , 2010, Molecular Cancer Therapeutics.
[13] J. Liao,et al. Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[14] N. Klugbauer,et al. The Nuclear Import of the Small GTPase Rac1 is Mediated by the Direct Interaction with Karyopherin α2 , 2010, Traffic.
[15] H. Shimokawa,et al. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[16] M. Wunderlich,et al. Transforming human blood stem and progenitor cells: A new way forward in leukemia modeling , 2008, Cell cycle.
[17] George Iliakis,et al. γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin , 2008, Nucleic acids research.
[18] U. Knaus,et al. P21-activated kinase is required for mitotic progression and regulates Plk1 , 2008, Oncogene.
[19] D. Williams,et al. Rac guanosine triphosphatases represent a potential target in AML , 2008, Leukemia.
[20] Yi Zheng,et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. , 2008, Cancer cell.
[21] David A. Williams,et al. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis , 2008, Leukemia.
[22] Jinshui Fan,et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. , 2008, Blood.
[23] C. Der,et al. Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. , 2008, Methods in enzymology.
[24] J Wade Harper,et al. The DNA damage response: ten years after. , 2007, Molecular cell.
[25] C. Der,et al. Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases* , 2007, Journal of Biological Chemistry.
[26] John G. Collard,et al. Rho GTPases: functions and association with cancer , 2007, Clinical & Experimental Metastasis.
[27] David A. Williams,et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. , 2007, Cancer cell.
[28] K. Cimprich,et al. The ATR pathway: fine-tuning the fork. , 2007, DNA repair.
[29] Hans Joenje,et al. Fanconi anemia and DNA replication repair. , 2007, DNA repair.
[30] J. Carroll,et al. Rac activity is polarized and regulates meiotic spindle stability and anchoring in mammalian oocytes. , 2007, Developmental cell.
[31] M. Cleary,et al. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.
[32] B. Kaina,et al. DNA damage-induced cell death by apoptosis. , 2006, Trends in molecular medicine.
[33] A. Ridley,et al. Rho GTPases and cell cycle control , 2006, Growth factors.
[34] F. Dammacco,et al. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. , 2005, Carcinogenesis.
[35] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[36] U. Laufs,et al. Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[37] Henk-Jan Guchelaar,et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.
[38] M. Minden,et al. Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis , 2004, Cancer Research.
[39] Kazuhiro Takahashi,et al. Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models* , 2004, Journal of Biological Chemistry.
[40] Yi Zheng,et al. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[41] J. Lacal,et al. Rho GTPases: potential candidates for anticancer therapy. , 2004, Cancer letters.
[42] P. Jeggo,et al. ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation , 2004, Cancer Research.
[43] R. Bonfil,et al. Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma , 1999, Clinical & Experimental Metastasis.
[44] P. Olive. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. , 2004, Methods in cell biology.
[45] W. Hiddemann,et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. , 2003, Blood.
[46] Kai Rothkamm,et al. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] M. Minden,et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.
[48] B. Halmos,et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. , 2002, Carcinogenesis.
[49] Jun Qin,et al. ATR and ATRIP: Partners in Checkpoint Signaling , 2001, Science.
[50] M. Minden,et al. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells , 2001, Leukemia.
[51] S. Coniglio,et al. Rac1 Protects Epithelial Cells against Anoikis* , 2001, The Journal of Biological Chemistry.
[52] L. Van Aelst,et al. Rho GTPases: signaling, migration, and invasion. , 2000, Experimental cell research.
[53] M. Jakóbisiak,et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] Zhenbiao Yang,et al. RHO Gtpases and the Actin Cytoskeleton , 2000 .
[55] G. Bokoch,et al. Regulation of cell function by rho family GTPases , 2000, Immunologic research.
[56] T. Rabbitts,et al. The Mll–AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis , 1999, The EMBO journal.
[57] M. Minden,et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. , 1999, Blood.
[58] K. Keyomarsi,et al. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53 , 1998, Oncogene.
[59] R. Bravo,et al. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. , 1997, Genes & development.
[60] M. Kastan,et al. Three paths to stress relief , 1996, Nature.
[61] M. Karin,et al. Selective activation of the JNK signaling cascadeand c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs , 1995, Cell.
[62] P. Crespo,et al. The small GTP-binding proteins Rac1 and Cdc42regulate the activity of the JNK/SAPK signaling pathway , 1995, Cell.
[63] J. Rowley,et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II , 1993 .